The gut microbiome is emerging as a key regulator of brain function and behavior and is associated with symptoms of several neurological disorders. There is emerging evidence that alterations in the gut microbiota are seen in epilepsy and in response to seizure interventions. In this review, we highlight recent studies reporting that individuals with refractory epilepsy exhibit altered composition of the gut microbiota. We further discuss antibiotic treatment and infection as microbiome-related factors that influence seizure susceptibility in humans and animal models. In addition, we evaluate how the microbiome may mediate effects of the ketogenic diet, probiotic treatment, and anti-epileptic drugs on reducing both seizure frequency and severity. Finally, we assess the open questions in interrogating roles for the microbiome in epilepsy and address the prospect that continued research may uncover fundamental insights for understanding risk factors for epilepsy, as well as novel approaches for treating refractory epilepsy. (E.Y. Hsiao).
Introduction
Epilepsy is a chronic neurological disorder affecting > 50 million people worldwide and accounting for 0.5% of the global economic disease burden (WHO, 2019) . It is defined as a brain pathology "characterized by an enduring predisposition to generate seizures" (Fisher et al., 2014 ). An estimated 2.4 million patients are diagnosed with epilepsy every year. These diagnoses include various subtypes of seizures, such as focal, generalized, combined generalized and focal, or unknown, which indicate their localization to specific brain regions or generalization across both cerebral hemispheres (Scheffer et al., 2017) . Seizures occur when excitation and inhibition are imbalanced in the brain, which can be triggered by pathologies affecting synaptic connectivity, ionic channel function, and neurotransmitter reception, among several other pathways (Stafstrom and Carmant, 2015) . Additionally, seizures can occur after cerebral insult or damage, as in the case of febrile seizures, traumatic brain injury, or stroke (Herman, 2002) .
While the WHO estimates that 70% of epileptic patients could be seizure-free with appropriate medication, in developing regions, less than half of the epileptic patient population has access to anti-epileptic drugs. Additionally, an estimated 15 million patients exhibit refractory epilepsy, based on their non-responsiveness to existing anti-epileptic drugs. Both genetic and environmental factors contribute to individual predisposition to epilepsy, but the exact causes of most epilepsy cases remain unclear. It is estimated that 35% of epilepsy cases can be directly attributed to genetic risk, while the remaining cases may involve both genetic risk and environmental exposures, such as head trauma or infections that lead to meningitis or encephalitis (Shorvon, 2014) .
Exactly how environmental factors contribute to long-term susceptibility to epilepsy remains unclear. The gut microbiota, comprising trillions of microorganisms indigenous to the gastrointestinal tract, is increasingly recognized as an important mediator of environmental risk factors on host risk for disease. The composition and function of the gut microbiota is shaped by environmental factors, such as diet, stress and medication, and also informed by human genetics. The microbiota plays a critical role in guiding brain development and neurobehavior in animal models (Vuong et al., 2017) . Of particular relevance to epilepsy, the gut microbiota significantly alters carbohydrate and amino acid metabolism, microglial and astrocytic function, vagal neuronal activity, and hippocampal neurotransmitter levels (Fung, 2017 #395) . In this review, we discuss current evidence for microbiome alterations in epilepsy and potential roles for the microbiome in mediating risk for epilepsy and the effects of seizure interventions (see Fig 1. ).
Alterations of the gut microbiota in human epilepsy
Alterations in the gut microbiome have been reported across several neurodevelopmental, neuropsychiatric and neurodegenerative disorders, but very little is known regarding microbiome associations with human epilepsy. Only a few recent studies have highlighted differences in fecal microbiota profiles from select epileptic individuals as compared to healthy controls (Table 1) (Lindefeldt et al., 2019; Peng et al., 2018; Xie et al., 2017) . In a cohort of 42 individuals with refractory epilepsy, 49 with drug-sensitive epilepsy, and 65 matched family members without epilepsy from West China Hospital of Sichuan University, 16S rDNA sequencing revealed distinct fecal microbiota alterations for refractory epileptic patients relative to both drug-sensitive epileptic patients and controls without epilepsy. In particular, microbiota profiles from the refractory epilepsy group exhibited elevated αdiversity, as measured by the Chao1 diversity index for species richness, which was reportedly particular to refractory epileptic patients with 4 or more seizures per year and not for those with < 4 seizures per year (Peng et al., 2018) . While samples from refractory epileptic patients exhibited no overt group clustering by weighted principal coordinate analysis, linear discriminant analysis (LDA) effect size analysis revealed increases in the relative abundances of select members of the phylum Firmicutes, including Roseburia, Coprococcus, Ruminococcus, and Coprobacillus, and decreases in Bacteroides relative to controls. Relative abundances of Methanobrevibacter, Fusobacterium, Neisseria, and Akkermansia were also increased in the refractory epilepsy group relative to the drug-sensitive epilepsy group. Notably, the study design matched group representation by age (mean 25.1-29.4), sex, and exposure to medication, and excluded individuals who had taken antibiotics or probiotics within the past 3 months or who had a history of another chronic disease. Primary differences between refractory and drug-sensitive groups were in seizure frequency and type (generalized, partial, or multiple), which would be expected based on the inherent biological features of the classifications. (See Table 1 .)
In another human study, fecal microbiota were profiled by 16S rDNA sequencing of stool samples collected from 14 infants with refractory epilepsy, ranging from 1 to 4 years old, and 30 matched healthy infants from Shenzhen Children's Hospital (Xie et al., 2017) . In this case, there was no significant difference in α-diversity between groups when measured by the Shannon index for evenness. However, principal component analysis showed clustering of 16S rDNA data from refractory epilepsy infants distinctly from healthy infant controls, indicating substantial differences in fecal microbial β-diversity. Similar to results from the Peng et al. study, LEfSe analysis revealed elevated relative abundance of Firmicutes and Proteobacteria, and reduced Bacteroidetes and Actinobacteria, in infants with refractory epilepsy. At the genus level, Cronobacter was highly enriched in epileptic infants and not detected in healthy infants, while relative levels of Bacteroides, Prevotella and Bifidobacterium were decreased in infants with refractory epilepsy relative to controls. While the study required participants to not have taken antibiotics 1 month prior to the study and excluded those with chronic illness or metabolic disease, baseline differences in infant diet which could confound the study in the absence of matched household controls were not considered.
A third human study of 12 children with refractory epilepsy, aged 2-17 years, and 11 healthy parent controls from Astrid Lindgren Children's Hospital of Karolinska Institute examined fecal microbiomes by shotgun metagenomic sequencing (Lindefeldt et al., 2019) . Fecal microbiota samples of children with refractory epilepsy exhibited decreased α-diversity, as measured by Shannon index, compared to microbiota samples from the healthy control parents. Principal component analysis of taxonomic and functional profiles revealed clear clustering of microbiomes from healthy control parents, whereas those from children with refractory epilepsy exhibited larger variation and minor shifts along the first principal component. In general, taxonomic analysis indicated that microbiota from children with refractory epilepsy displayed decreased relative abundances of Bacteroidetes and Proteobacteria and increased relative abundances of Firmicutes and Actinobacteria, when compared to control parent samples. Particular differences in functional potential were reported, with refractory epilepsy microbiomes harboring decreased gene content for β-hydroxybutyryl-CoA dehydrogenase and crotonase, genes involved in the acetyl-CoA pathway, as compared to parent control microbiomes. In light of known age-dependent changes in the gut microbiome, a key caveat of these comparisons is the lack of age-matched controls.
Overall, all three of these human studies report alterations in the fecal microbiota of individuals with refractory epilepsy relative to varied non-epileptic controls (Lindefeldt et al., 2019; Peng et al., 2018; Xie et al., 2017) . While they each report increased Firmicutes relative to Bacteroides in individuals with refractory epilepsy, the reported microbial alterations varied highly across taxonomic levels more resolved than phylum. In addition, the results were conflicting with regard to whether α-diversity is altered in the epilepsy microbiota. These studies are difficult to cross-compare due to variations in study design, age differences of subjects, relatively small samples sizes, as well as a lack of data on genetic and environmental factors that could influence the structure and function of the gut microbiome. Additionally, these studies differ by sequencing methodology and analytical tools used to profile the gut microbiota, where shotgun metagenomics, as in the Lindefeldt study, delivers both strain specificity and microbiome functional profiling, while 16S rDNA taxonomic profiling captures broader, less specific levels of diversity (Poretsky et al, 2014) . Larger efforts are needed to achieve adequately powered patient and control populations and to account for variables such as age, human genetics, medication, and diet.
Microbiome associations with Epileptogenesis

The gut microbiota and seizure susceptibility in animal models
In addition to the existing human studies reporting a correlation Fig. 1 . Potential roles for the gut microbiome in mediating risk factors (red) and interventions (blue) for epilepsy. Factors associated with increased susceptibility to seizures, including antibiotics, infection, and psychological and physical stressors, also perturb the gut microbiota. Antibiotics can promote seizures directly through modulation of neuronal activity, or indirectly through modification of the microbiome. Pro-inflammatory cytokines and stress hormones that promote seizure risk can be induced by microbial antigens and can modify the gut microbiome. Particular gut microbes may alter the metabolism of antiepileptic drugs or be directly inhibited by antiepileptic drugs. The ketogenic diet is used to treat refractory epilepsy and is associated with changes in both the human and mouse gut microbiome. In two human studies, probiotic treatment was associated with reduced seizure risk. Separate animal studies report that probiotics modulate brain expression of gamma-aminobutyric acid (GABA) receptors, levels of GABA relative to glutamate, and seizure susceptibility. Decrease in Firmicutes and Actinobacteria
During KD treatment 2 children were seizure free, 3 children had 90-99% reduction in seizure frequency, 5 children had 50-89% reduction in seizure frequency KD = ketogenic diet, GLUT1 DS = glucose transporter type 1 deficiency syndrome.
between refractory epilepsy and altered gut microbiota, a few animal studies highlight a causal role for the microbiome in modulating seizure susceptibility. Animal models for studying epilepsy include the use of chemoconvulsants such as kainic acid, electrical stimulation using the 6 Hz seizure model, or seizure kindling which applies repeated stimulation to increase seizure susceptibility. One in particular drew upon a wealth of literature reporting that physical and psychological stressors alter the gut microbiota (Vuong et al., 2017) to further investigate whether stress-induced alterations in the gut microbiota impact the development of seizures (Medel-Matus et al., 2018) . Sprague-Dawley rats were subjected to sham stress or chronic restraint stress for two 2-h long sessions per day for 2 weeks, and cecal contents from each group were then transplanted into naïve recipient rats that were pre-treated with antibiotics to first deplete the gut microbiome. As expected, rats exposed to chronic restraint stress required fewer number of trials of basolateral amygdalar stimulation in order to induce a full seizure response and longer seizure duration, when compared to sham stress controls. This is consistent with prior studies revealing that stress promotes epileptogenesis. Notably, transplantation of the microbiome from a stressed rat into non-stressed recipient sufficiently conferred the stress-related increases in susceptibility to kindling and duration of seizures. In contrast, transplantation of the microbiome from a nonstressed rat into a stressed rat sufficiently reduced seizure duration and increased the number of kindling trials toward levels seen in the native sham controls. These results suggest that the microbiome mediates stress-induced increases in seizure susceptibility in a rat kindling model. Limitations of the study include the small sample size of 6 rats per group, the lack of companion sequencing data to identify taxonomic and functional differences in the microbiome that underlie their proversus anti-epileptic effects, and the lack of sequencing data of donor and recipient microbiota to confirm high fidelity transplantation. Additionally, mechanisms underlying the effects of transplantation on seizure susceptibility remain unclear; it is possible that metabolites contained within the transplant material, rather than the microbiome itself, could play a role, as could any indirect effects of the procedure on the host stress response. A separate study examined links between the microbiome and the formation of cerebral cavernous malformations (CCMs), structural abnormalities in brain capillaries that predispose to stroke and seizures (Tang et al., 2017) . Initial observations in endothelial specific Krit1 ECKO and Ccm2 ECKO knockout mice, which are theoretically susceptible to CCM formation, revealed that differences in the breeding vivarium and unexpected infections modulated resistance vs. susceptibility to CCM formation. Follow-up experiments demonstrated that intraperitoneal injection of the gram-negative bacterium B. fragilis or lipopolysaccharide were each sufficient to drive CCM formation through TLR4 signaling. These results suggest that infection with gram negative bacteria (GNB) or systemic injection of GNB-associated antigens accelerates CCM formation. Further supporting a role for the gut microbiome on CCM formation, Krit1 ECKO mice raised as germ-free failed to form CCM lesions, whereas those raised conventionally colonized developed CCMs by P10. Consistent with this, maternal antibiotic treatment yielded offspring that were resistant to CCM formation, a phenotype that was transmitted transgenerationally to mice in the absence of antibiotic treatment. In contrast, conventionalization of the microbiome by cross-fostering to conventionally-colonized mothers restored susceptibility to CCM formation. 16S rDNA sequencing of fecal samples from CCM susceptible versus resistant Krit1 ECKO and Ccm2 ECKO mice revealed distinct group clustering of microbiota profiles by principal coordinates analysis. Taxonomic analysis highlighted significantly increased relative abundance of Bacteroidetes S24-7 in mice susceptible to CCM formation, as compared to resistant controls. Whether this particular taxon is sufficient to modulate CCM formation is unclear. However, the several experiments performed in the study reveal a causal relationship between the gut microbiota and formation of CCMs, a primary risk factor for seizures. Altogether, mechanistic studies in animal models have begun to highlight how the gut microbiota could modify seizure vulnerability.
Infection and risk for epilepsy
Several large epidemiological and case studies associate infections with increased risk for epilepsy. A singleton cohort study of all children born in northern Denmark from 1998 to 2008 reported increased risk for epilepsy in children born from mothers that experienced infection during pregnancy (Ahlers et al., 2019; Norgaard et al., 2012) . Similarly, in a nationwide population-based cohort study of all individuals born in Denmark from 1982 to 2012, childhood infection with hospitalization was associated with a 78% increase in risk for epilepsy (Ahlers et al., 2019) . Consistent with this, infants infected with Group B streptococcus, a leading cause of neonatal morbidity, are more likely to be hospitalized and diagnosed with epilepsy or other neurological conditions during their childhood years (Yeo et al., 2019) . A study conducted by the Norwegian Institute of Public Health reported an increase in febrile seizures characteristic of febrile infection-related epilepsy syndrome (FIRES) following the 2009 influenza A (H1N1) pandemic (Bakken et al., 2015) . In addition, human herpesvirus (HHV)-6 infection has been associated with mesial temporal sclerosis (MTS), a common pathological marker in mesial temporal lobe epilepsy (MTLE), and the HHV6-B virus in particular is linked with childhood epilepsy (Leibovitch and Jacobson, 2015; Vezzani et al., 2016) . In a study of 75 MTLE patients, 52 patients displaying MTS and 23 non-MTS patients, MTS patients exhibited a greater number of seizures, increased HHV-6 viral DNA load and increased markers of inflammation compared to non-MTS controls (Kawamura et al., 2015) . Other studies have also suggested that HHV-6 drives MTS/MTLE pathogenesis by inducing abnormal immune or inflammatory responses (Bartolini et al., 2019; Wipfler et al., 2018) . Additional human studies of bacterial and parasitic infections also suggest links between infection and seizure susceptibility. Taenia solium, a tapeworm with prevalence in the regions around Burkina Faso causes neurocysticercosis in infected humans, which correlates with the prevalence of epilepsy in low income countries (Sahlu et al., 2019; Vezzani et al., 2016) . Overall, the diversity of infections implicated in epilepsy has led to the notion that generalized immune activation or inflammation promotes susceptibility to seizures (Pardo et al., 2014; Tan, 2018) .
Animal models of various infections support a causal role for inflammation in promoting seizure vulnerability. As a model of limbic epilepsy, mice injected intracortically with Theiler's murine encephalomyelitis virus (TMEV) exhibited seizures and neuroinflammation characterized by elevated pro-inflammatory cytokines including interleukin (IL)-6 and tumor necrosis factor (TNF)⍺ in the hippocampus, a focal region for seizure initiation (Cusick et al., 2017; Patel et al., 2017) . Notably, blocking TNF signaling by TMEV injection into TNF⍺ −/− or TNFR1 −/-TNFR2 −/− mice sufficiently reduced seizures, suggesting that TNF signaling is required for mediating the pro-epileptic effects of TMEV infection. The study provided evidence that TNFα modulates glutamate receptor trafficking via TNF receptor 1 to increase excitatory synaptic transmission, which could underlie the elevated seizure incidence seen in response to TMEV. In a separate study, Wistar rats injected systemically with the bacterial cell wall component lipopolysaccharide (Veitenhansl et al., 2004) exhibited elevated levels of pro-inflammatory cytokines TNF⍺, IL-6, and IL-1β in the brain and decreased thresholds for chemically-and electrically-induced seizures by pentylenetetrazole (PTZ) and corneal shock, respectively (Sewal et al., 2017) . In addition, toxoplasma-infected mice displayed reduced PTZ-induced seizures as well, which were partially abrogated by blocking the dopamine receptors D1 and D2 (Babaie et al., 2017) . Altogether, these animal studies corroborate human association studies by revealing that a broad range of bacteria, viruses, and parasites can similarly promote seizure propensity. Research further suggests that inflammatory responses associated with cytokines and chemokines such as TNF⍺ (Cusick et al., 2017; Patel et al., 2017; Sewal et al., 2017) and MCP-1 (Kawamura et al., 2015) could mediate the proepileptic effects of infection.
Antibiotic treatment and seizure susceptibility
Antibiotics are commonly prescribed for treating bacterial infections (Tamma et al., 2017) but despite their widespread use, many can elicit adverse side effects, including neurological symptoms (Mattappalil and Mergenhagen, 2014) . A large epidemiological study of the Danish registry reported that increased numbers of antibiotic prescriptions for a single patient correlate with increased risk for epilepsy (Norgaard et al., 2012) . Another study reported increased seizure risk in hemodialysis patients that were administered cephalosporin antibiotics (Zhang et al., 2019) . A meta-analysis of all randomized controlled human trials of carbapenem antibiotics reported a significant increase in seizure risk associated with carbapenem usage (Cannon et al., 2014) . Imipenem and meropenem antibiotics were also highly correlated with epileptogenesis (Leibovitch and Jacobson, 2015; Owens Jr., 2008) . While the majority of studies point to neurotoxic effects of antibiotics, such as β-lactams, unsubstituted penicillins, carbapenems, and 4th generation cephalosporins (Esposito et al., 2017; Sutter et al., 2015) , a few small cohort and case studies have explored antibiotics as potential treatments for epilepsy (Braakman and van Ingen, 2018; Ghanizadeh and Berk, 2015; Raposo et al., 2016; Ghanizadeh and Berk, 2015) . One found that treatment with a combination of penicillin derivative and macrolide antibiotics coincided with temporary seizure-free periods in six epileptic individuals (Braakman and van Ingen, 2018) . Another reported that cefixime usage correlated with seizure-free bouts in a 9 year old boy with epilepsy and comorbid autism (Ghanizadeh and Berk, 2015) . A challenge to interpreting the existing human data is the inability to distinguish potential off-target effects of antibiotics from their indicated anti-bacterial effects.
Findings from laboratory models have studied potential pathways by which antibiotics regulate seizure susceptibility. Particular β-lactam antibiotics are sufficient to elicit focal seizures in mice when injected intracortically or intracerebroventricularly. For example, penicillin-inducible seizure models have been used in multiple studies to understand epileptogenesis (Arslan et al., 2017; Han et al., 2015; Marangoz et al., 2018; Tubas et al., 2017; Zhu et al., 2018) . The epileptogenic potential of penicillin, among other antibiotics, has been attributed to the antagonism of gamma-aminobutyric acid (GABA) -A receptors by the β-lactam ring (Veitenhansl et al., 2004) . Non-competitive inhibition in this manner and voltage-dependent alterations are thought to reduce GABAergic inhibition and thereby permit excitatory signaling to trigger epileptiform bursts. In addition to inhibiting GABA-A receptors, quinolones can also bind to benzodiazepine receptors in the GABA complex. Moreover, both quinolones and cephalosporins further display agonistic effects on glutamatergic N-methyl-D-aspartate (NMDA) receptors, which further promote seizure susceptibility. Carbapenems, which are most frequently associated with seizures, have a higher potential to promote seizures due to their greater ability to cross the blood brain barrier and to interfere with the action of antiepileptic drugs such as valproic acid.
In contrast to these direct effects of particular antibiotics on promoting neuronal activity underling seizures, some drugs with antimicrobial properties are being pursued for their anti-epileptic effects. Rapamycin, an mTOR inhibitor and antibiotic, reduced mTOR activation, overexpression of P-glycoprotein, and seizure susceptibility in a rat Coriaria lactone kindling model of temporal lobe epilepsy (Mazumder et al., 2016; Plovier et al., 2017) . Minocycline, an inhibitor of microglial activation and antibiotic, reduced sympathetic nerve activity and increased seizure thresholds in rat kainic acid and amygdalar kindling seizure models (Beheshti Nasr et al., 2013; Bhandare et al., 2017) . In addition, the antibiotic gentamicin increased latency to seizure and reduced total seizure duration when injected intracerebroventricularly into rats treated with kainic acid (Zhao et al., 2018) . Overall, both human and animal studies have reported opposing effects of different antibiotics on seizure susceptibility. The findings warrant increased attention to whether the particular type, dose and route of antibiotic treatment may elicit disparate influences on vulnerability to particular subtypes of seizures.
Microbiome implications for epilepsy treatments
The microbiome and ketogenic diet
The high-fat, low-carbohydrate ketogenic diet (KD) is used as a clinical treatment for refractory epilepsy in individuals who do not respond to existing anti-epileptic drugs. While the KD has been used for almost a century for reducing seizures, the exact mechanisms by which the diet ameliorates seizures remains unclear. A few recent studies have investigated effects of the clinical KD on the composition of the gut microbiome in epilepsy patients, drawing the attention to whether alterations in the gut microbiome may contribute to the protective effects of the KD against seizures. In a study of 12 children diagnosed with drug-resistant epilepsy, 5 out of 12 children displayed a > 50% decrease in seizure reduction and 10 out of the 12 children exhibited improved cognition and motor functions after 3 months on classical KD (Lindefeldt et al., 2019) . When comparing the gut microbiome samples collected before initiation of the KD to those taken after 3 months on KD, there was no significant difference in α-diversity. However, β-diversity analysis revealed compositional differences characterized by decreases in relative abundances of Actinobacteria and Bifidobacterium and an increase in Proteobacteria. Another study of 20 children with refractory epilepsy reported KD-associated reductions in epilepsy symptoms that were correlated with reduced α-diversity of the microbiome, decreases in Actinobacteria and Firmicutes relative to Bacteroidetes after 6 months of dietary treatment . A third study of 14 epileptic infants reported reductions in Proteobacteria and elevations in Bacteroides, Prevotella, and Bifidobacterium after at least 1 week on the KD (Xie et al., 2017) . There was little consistency across these studies in the particular microbial taxa that were affected, which could be due to variations in study design, such as the length of KD treatment, the specific KD dietary regimen implemented, and the subtypes of epilepsy and seizure semiologies represented by the patient cohorts. One study examined 6 patients diagnosed particularly with glucose transporter 1 deficiency syndrome (GLUT1 DS) (Tagliabue et al., 2017) . 3 months of KD treatment correlated with alterations in the gut microbiome that were characterized by a decrease in the relative abundance of Desulfovibrio. Overall, these studies warrant continued efforts to examine the effects of the KD on the gut microbiome across a large cohort of epileptic individuals. In particular, profiling microbial function rather than taxonomy, and examining associations with particular dietary, seizure semiology, medical history, and demographic data may yield greater insight across studies.
Additional studies in animal models of epilepsy similarly reveal functional roles for the gut microbiome in mediating the anti-seizure effects of the diet. In a 6 Hz acute electrically-induced seizure model of refractory epilepsy, depletion of the gut microbiome by antibiotic treatment or germ-free rearing abrogated the protective effects of the KD (Olson et al., 2018) . Moreover, promoting the KD-associated microbiome in naïve mice fed a control diet sufficiently conferred seizure protection. 16S rDNA sequencing revealed that the KD decreased αdiversity of the gut microbiome within 4 days of dietary treatment and increased the relative abundance of Akkermansia muciniphila, Parabacteroides, Sutterella, and Erysipelotrichaceae relative to controls. Selective enrichment of A. muciniphila and Parabacteroides conferred protection against 6 Hz seizures. These findings were further replicated in the Kcna1 −/− genetic mouse model for sudden unexpected death in epilepsy (SUDEP), where depletion of the gut microbiome promoted spontaneous tonic-clonic seizures whereas selective enrichment of KD-associated bacterial taxa reduced seizure frequency and duration. Metabolomic data revealed decreases in peripheral ketogenic gammaglutamylated amino acid concentrations, which correlated with higher hippocampal GABA/glutamate ratios in seizure protected mice, suggesting a role for microbial regulation of peripheral metabolites and central neurotransmitter metabolism in regulating seizure susceptibility. These findings align with increasing interest in select microbes that regulate the biosynthesis of GABA within the gut (Strandwitz, 2018; Yunes et al., 2016) , and the use of other microbiota-related metabolites to modulate seizure susceptibility. For example, ginsenoside compound K was reported to decrease seizure intensity and latency in rats challenged with pentylenetetrazole to induce seizures (Zeng et al., 2018) , and GPR40, a receptor for free fatty acids, has been shown to also regulate NMDA receptor function to reduced seizure susceptibility (Yang et al., 2018) . Additional studies are needed to examine mechanisms by which microbes and microbiome-dependent metabolites influence brain activity and behavior related to epilepsy.
Probiotic treatment in human epilepsy
Although there have been only a few small studies to date that report alterations in the gut microbiome in human epilepsy (Liang et al., 2017; Lindefeldt et al., 2019; Xie et al., 2017) , the links between epilepsy and infection, inflammation and antibiotic treatment raise the question of whether microbial alterations under those conditions may play a role. Two recent human studies examined the effects of probiotics on seizures. In an observational study of neonates infected with rotavirus at the Gyeongsang National University Hospital (Yeom et al., 2019) , 32 out of the 78 rotavirus positive neonates and 100 out of 150 rotavirus negative neonates were treated with Saccharomyces boulardii or Lactobacillus casei as a probiotic within 24 h of birth. The authors proposed that S. boulardii reduces seizures through inhibition of rotavirus structural protein 4, a viral enterotoxin which increases reactive oxygen species and white matter injurty, or through suppressing the inflammatory response overall. The study reported that probiotic administration within 24 h of birth was associated with a 10-fold decreased risk for seizures (odds ratio of 0.09) while rotavirus infection remained a risk factor only in neonates not given probiotics (odds ratio of 4.83). Seizure reduction was also reported in a pilot open label study of 43 adults with drug-resistant epilepsy treated daily for 4 months with a cocktail of Lactobacillus acidophilus, L. plantarum, L. casei, L. helveticus, L. brevis, Bifidobacterium lactis, and Streptococcus salivarius (Gomez-Eguilaz et al., 2018) . 13 out of 43 (30%) of individuals reported > 50% reduction in seizure frequency in the 4 months post treatment; however, a major limitation is the small study size and lack of placebo control. In addition to probiotic treatment, one recent case study from the Second Affiliated Hospital of Nanjing Medical University performed fecal microbiota transplantation (FMT) to treat Crohn's disease (CD) in a 22-year-old individual with refractory epilepsy . After 3 treatments, there was a decrease in the patient's CD index score from 361 (pre FMT) to 131 (20 months post-FMT). In addition, the patient reportedly experienced no epileptic seizures during the 20 months after FMT during which no antiseizure medications were taken. Consistent with this potential role for select probiotics to modulate seizure susceptibility, two studies in rodent models reported that probiotic treatment with L. rhamnosus alone or together with B. longum modulated expression of select GABA receptor subunits in various brain regions (Bravo et al., 2011; Liang et al., 2017) . Overall, the promising results from the limited human and animal studies performed to date suggest that additional studies are needed to examine whether manipulation of the gut microbiome may serve as a tractable strategy for reducing seizures.
Anti-epileptic drugs and the gut microbiota
Non-antibiotic medications, including anti-epileptic drugs, can interact directly with gut microbes that modify their metabolism and thereby impact drug efficacy and toxicity. A recent study of 1197 medications reported that 27% of non-antibiotic drugs inhibited the growth of at least one of 40 bacterial isolates (Maier et al., 2018) . An additional study reported that the anticonvulsant drug clonazepam is metabolized by intestinal microbes, which can contribute to drug toxicity (Zimmermann et al., 2019) . Other studies report mild effects of anti-seizure treatments such as carbamazepine on select gut microbes (Gomes et al., 2018; Vasiliadou et al., 2018; Watkins et al., 2017) . Moreover, in a mouse study of maternal treatment with the antiepileptic drug valproic acid (Veitenhansl et al.) , offspring of valproic acid (VPA)-treated mothers exhibited fecal microbiota with decreased Firmicutes and increased Bacteroidetes when compared to vehicle-exposed control mice (Sgritta et al., 2019) . Additional animal studies similarly report that maternal exposure to VPA alters offspring gut microbiota composition (de Theije et al., 2014; Lim et al., 2017; Liu et al., 2018) . Notably, VPA during pregnancy has known teratogenic effects, which raises the question of whether select VPA-induced phenotypes occur via microbiome alterations as opposed to other direct effects of VPA on host physiology. These studies highlight the importance of considering drug-induced gut microbiota changes and direct xenobiotic interactions with gut microbes. Large well-controlled population studies are needed to determine whether there is a clear signature of microbiome alterations in human epilepsy, and further, whether any antiepileptic drugs may alter the microbiome in a reproducible manner.
Conclusion
The gut microbiota is increasingly recognized as an important factor in epilepsy. Epilepsy is a highly heterogeneous disorder requiring understanding of interactions between genetic and environment risk. The gut microbiota regulates immunity and inflammation, metabolism, and peripheral and central neuronal signaling, pathways independently linked to epileptogenesis. Continued studies are warranted to understand the gut microbiota as a mediator of environmental variables, like diet, stress, and immune challenge, on seizure outcomes. Despite human studies demonstrating that changes in the composition of the microbiota correlate with epilepsy, there is as yet little consistency in the exact microbial taxa implicated across studies. The microbiome studies in epileptic patients to date are few, underpowered, and focus largely on bacterial taxa rather than function. Future studies that evaluate functional metagenomic profiles of the microbiome in large cohorts of epileptic individuals and age-matched controls, with careful consideration of seizure semiologies, demographic, medical and dietary information, could reveal whether there are consistent functional microbial signatures for subtypes of epilepsy. Such studies have the potential to uncover whether the gut microbiome can serve as a novel biomarker of subtypes of epilepsy. Absent of consistent microbiome implications with epilepsy pathogenesis, the gut microbiome could influence efficacy of seizure treatments, such as the ketogenic diet and anti-epileptic drugs. Further study of how the microbiome is impacted by seizure interventions could identify microbial markers for treatment responsiveness or form the foundation for novel microbiome-based treatments for epilepsy. Finally, detailed studies in animal models, for how microbes impact brain metabolism, neuroimmunity and neuronal activity promise to uncover fundamental principles for host-microbiome interactions that impact brain and behavior. Overall, further investigation into roles for the microbiome in epilepsy could help to uncover mechanistic underpinnings of epilepsy pathogenesis, biomarkers for disease and therapeutic responsivity, and novel approaches for treatment of refractory epilepsy. supported by a Packard Fellowship in Science and Engineering, Chan Zuckerberg Initiative Ben Barres Career Acceleration Award and Department of Defense Army Research Office Multidisciplinary University Research Initiative Award.
